Analysts have nudged their fair value estimate for GoodRx Holdings slightly lower, from about US$4.95 to roughly US$4.56 per share, while also modestly increasing the discount rate from around 9.79% ...

GoodRx Holdings Inc. (NASDAQ:GDRX), a leading healthcare technology company specializing in prescription drug discounts and telehealth services, finds itself at a critical juncture. As the company ...

Shares of GoodRx have fallen ~20% over the past year. Amid hopes for growth via direct relationships with pharmaceutical manufacturers, the company may have hit a near-term bottom. GDRX returned to ...

GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of Ozempic (semaglutide) and Wegovy (semaglutide) pens are available to eligible ...

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes.

Ratings for GoodRx Holdings (NASDAQ:GDRX) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their ...

GoodRx stock rated a sell due to industry headwinds, cost growth outpacing revenue, and needing 12%+ growth to justify price. Q2 earnings expected to be in line with guidance, but long-term guidance ...

Leerink Partners analyst Michael Cherny has reiterated their bullish stance on GDRX stock, giving a Buy rating on November 13. Don't Miss our Black Friday Offers: Unlock your investing potential with ...

Shares of 60 Degrees Pharmaceuticals Inc (NASDAQ:SXTP) fell about 16.9% in premarket trading on Monday after the company ...